These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25294909)

  • 1. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.
    Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B
    Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.
    Yoo JY; Haseley A; Bratasz A; Chiocca EA; Zhang J; Powell K; Kaur B
    Mol Ther; 2012 Feb; 20(2):287-97. PubMed ID: 22031239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model.
    Xiao B; Ying C; Chen Y; Huang F; Wang B; Fang H; Guo W; Liu T; Zhou X; Huang B; Liu X; Wang Y
    J Cell Mol Med; 2020 Nov; 24(22):13431-13439. PubMed ID: 33251723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
    Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
    Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
    Clin Cancer Res; 2019 Mar; 25(5):1624-1638. PubMed ID: 30206160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.
    Lin SF; Gao SP; Price DL; Li S; Chou TC; Singh P; Huang YY; Fong Y; Wong RJ
    Clin Cancer Res; 2008 Mar; 14(5):1519-28. PubMed ID: 18316577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
    Skelding KA; Barry RD; Shafren DR
    Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
    Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
    Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
    Dong W; van Ginkel JW; Au KY; Alemany R; Meulenberg JJ; van Beusechem VW
    Hum Gene Ther; 2014 Oct; 25(10):897-904. PubMed ID: 25093639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer.
    Huang S; Hu H; Tang G; Liu K; Luo Z; Zeng W
    Arch Virol; 2023 Mar; 168(4):128. PubMed ID: 37002434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
    Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
    PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
    Okemoto K; Kasai K; Wagner B; Haseley A; Meisen H; Bolyard C; Mo X; Wehr A; Lehman A; Fernandez S; Kaur B; Chiocca EA
    Clin Cancer Res; 2013 Nov; 19(21):5952-9. PubMed ID: 24056786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Siurala M; Bramante S; Vassilev L; Hirvinen M; Parviainen S; Tähtinen S; Guse K; Cerullo V; Kanerva A; Kipar A; Vähä-Koskela M; Hemminki A
    Int J Cancer; 2015 Feb; 136(4):945-54. PubMed ID: 24975392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer.
    Alfano A; Cafferata EGA; Gangemi M; Nicola Candia A; Malnero CM; Bermudez I; Lopez MV; Ríos GD; Rotondaro C; Cuneo N; Curiel DT; Podhajcer OL; Lopez MV
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
    Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.